Compare Stocks → Putin and other countries have a plan (From Whats On Finance) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ATOSNASDAQ:BLCMOTCMKTS:COTQFNASDAQ:HSTO Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATOSAtossa Therapeutics$1.49+4.9%$1.40$0.59▼$2.31$186.70M1.191.40 million shs1.14 million shsBLCMBellicum Pharmaceuticals$0.07-6.6%$0.08$0.06▼$1.31$727K1.3922,874 shs6,000 shsCOTQFCotinga Pharmaceuticals$0.00$0.00▼$0.00N/AN/AN/AN/AHSTOHistogen$0.35+133.3%$0.38$0.05▼$1.05$1.49M0.9221,793 shs5,277 shs10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATOSAtossa Therapeutics+3.65%-16.96%-14.97%+72.50%+102.86%BLCMBellicum Pharmaceuticals0.00%0.00%0.00%-25.20%-77.84%COTQFCotinga Pharmaceuticals0.00%0.00%0.00%0.00%0.00%HSTOHistogen+133.33%-30.00%+7.69%+3.86%-64.23%The system that called 2023’s top 7 stocks is at it again… (Ad)Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.Just follow this link here!MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATOSAtossa Therapeutics1.0302 of 5 stars3.51.00.00.01.71.70.0BLCMBellicum PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACOTQFCotinga PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AHSTOHistogenN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATOSAtossa Therapeutics3.00Buy$4.50202.01% UpsideBLCMBellicum PharmaceuticalsN/AN/AN/AN/ACOTQFCotinga PharmaceuticalsN/AN/AN/AN/AHSTOHistogenN/AN/AN/AN/ACurrent Analyst RatingsLatest BLCM, ATOS, COTQF, and HSTO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/16/2024ATOSAtossa TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.004/2/2024ATOSAtossa TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.002/12/2024ATOSAtossa TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$4.00(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATOSAtossa TherapeuticsN/AN/AN/AN/A$0.73 per shareN/ABLCMBellicum Pharmaceuticals$1.50M0.48N/AN/A$0.23 per share0.33COTQFCotinga PharmaceuticalsN/AN/AN/AN/AN/AN/AHSTOHistogen$3.77M0.40N/AN/A$3.13 per share0.11Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATOSAtossa Therapeutics-$30.09M-$0.24N/AN/AN/AN/A-31.01%-29.77%5/20/2024 (Estimated)BLCMBellicum Pharmaceuticals-$24.97MN/A0.00∞N/AN/AN/A-157.93%N/ACOTQFCotinga PharmaceuticalsN/AN/A0.00N/AN/AN/AN/AN/AN/AHSTOHistogen-$10.62M-$2.81N/A∞N/A-65,142.11%-136.13%-90.87%N/ALatest BLCM, ATOS, COTQF, and HSTO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/1/2024Q4 2023ATOSAtossa TherapeuticsN/A-$0.06-$0.06-$0.06N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATOSAtossa TherapeuticsN/AN/AN/AN/AN/ABLCMBellicum PharmaceuticalsN/AN/AN/AN/AN/ACOTQFCotinga PharmaceuticalsN/AN/AN/AN/AN/AHSTOHistogenN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATOSAtossa TherapeuticsN/A17.6117.61BLCMBellicum PharmaceuticalsN/A3.043.04COTQFCotinga PharmaceuticalsN/AN/AN/AHSTOHistogenN/A4.054.05OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATOSAtossa Therapeutics12.74%BLCMBellicum Pharmaceuticals4.93%COTQFCotinga PharmaceuticalsN/AHSTOHistogenN/AInsider OwnershipCompanyInsider OwnershipATOSAtossa Therapeutics7.80%BLCMBellicum Pharmaceuticals10.30%COTQFCotinga PharmaceuticalsN/AHSTOHistogen3.30%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableATOSAtossa Therapeutics12125.30 million115.53 millionOptionableBLCMBellicum Pharmaceuticals139.72 million8.72 millionNot OptionableCOTQFCotinga PharmaceuticalsN/AN/AN/ANot OptionableHSTOHistogen74.27 million4.13 millionNot OptionableBLCM, ATOS, COTQF, and HSTO HeadlinesSourceHeadlineHistogen Inc: Histogen Files for Voluntary Chapter 11 Protection to Facilitate Wind-Down, Maximize Share Offeringfinanznachrichten.de - April 22 at 9:19 AMHistogen Files For Voluntary Chapter 11 Bankruptcy Protectionmarkets.businessinsider.com - April 18 at 11:31 PMHistogen files for Chapter 11, seeks liquidationmsn.com - April 18 at 6:31 PMHistogen Files for Voluntary Chapter 11 Protection to Facilitate Wind-Down, Maximize Share Offeringglobenewswire.com - April 18 at 5:29 PMHistogen Stock (OTC:HSTO) Dividends: History, Yield and Datesbenzinga.com - February 6 at 3:17 PMHistogen Announces Second Adjournment of Special Meeting of Stockholdersfinance.yahoo.com - December 14 at 6:46 PMHistogen Inc: Histogen Announces Adjournment of Special Meeting of Stockholdersfinanznachrichten.de - December 6 at 7:27 PMHistogen Announces Adjournment of Special Meeting of Stockholdersfinance.yahoo.com - December 5 at 6:26 PMHistogen Inc HSTOmorningstar.com - November 1 at 7:12 AMDays-to-cover ratio for HSTO surges to 4.25 due to rise in short interestknoxdaily.com - October 5 at 8:14 PMHSTO short interest fall by -56.24%, reflecting positive sentimentknoxdaily.com - September 21 at 3:17 PMWall Street Set to Open Wednesday Trading Higher as Investors Await Fed Decision on Interest Ratesmsn.com - September 21 at 10:17 AMU.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.31%msn.com - September 20 at 6:11 PMHistogen Inc: Histogen Announces Board Approval of Complete Liquidation and Dissolutionfinanznachrichten.de - September 20 at 6:11 PMMagnet attracts $50M series A for efforts with molecular gluesbioworld.com - September 20 at 8:10 AMHistogen Board Approves To Dissolve And Wind Down Operationsmarkets.businessinsider.com - September 20 at 1:17 AMU.S. shares lower at close of trade; Dow Jones Industrial Average down 0.31%msn.com - September 19 at 8:16 PMBiotech firm Histogen to wind down after failing to raise capitalmsn.com - September 18 at 6:27 PMHistogen Announces Board Approval of Complete Liquidation and Dissolutionfinance.yahoo.com - September 18 at 6:27 PMHistogen views strategic alternativesthepharmaletter.com - July 7 at 9:13 AMHistogen shares are trading higher after the company decided to pause further development of its programs, commence exploring strategic alternatives.benzinga.com - July 6 at 7:06 PMHistogen plans to commence strategic alternatives processseekingalpha.com - July 5 at 7:16 PMHistogen to Explore Strategic Alternativesfinance.yahoo.com - July 5 at 7:16 PMAsia Pacific Alopecia Treatment Market to See Booming Worldwide ... - Digital Journalnews.google.com - May 13 at 8:35 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAtossa TherapeuticsNASDAQ:ATOSAtossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition, the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.Bellicum PharmaceuticalsNASDAQ:BLCMBellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.Cotinga PharmaceuticalsOTCMKTS:COTQFCotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.HistogenNASDAQ:HSTOHistogen Inc., a clinical-stage therapeutics company, focuses on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body's natural process to restore immune function. The company's product candidates include emricasan for the treatment of acute bacterial skin and skin structure infections, as well as other infectious diseases. Its preclinical product candidates include CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of various inflammatory diseases. Histogen Inc. was founded in 2007 and is based in San Diego, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.